Pulmatrix Inc Stock price history chart earnings

Pulmatrix Inc Stock price history chart earnings

Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations.

ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities. © 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information unreal for unity developers is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer. Pulmatrix’s stock was trading at $8.76 at the beginning of the year.

• Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations.
• Pulmatrix saw a decrease in short interest in the month of October.
• Intraday data delayed at least 15 minutes or per exchange requirements.
• That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.
• Pulmatrix Inc. is a clinical stage biotechnology company, which engages in the discovery and development of novel inhaled therapeutic products for respiratory and other diseases.
• Test Pulmatrix, Inc. is a clinical stage biotechnology company, which engages in the discovery and development of novel inhaled therapeutic products for respiratory and other diseases.

The company’s shares closed last Wednesday at $0.83, close to its 52-week low of $0.7… The technique has proven to be very useful for finding positive surprises. In fact, when combining a Zacks Rank #3 or better and a positive Earnings ESP, stocks produced a positive surprise 70% of the time, while they also saw 28.3% annual returns on average, according to our 10 year backtest. Pulmatrix’s stock reverse split before market open on Tuesday, March 1st 2022.

Based on an average daily trading volume, of 94,400 shares, the short-interest ratio is presently 0.6 days. Currently, 1.6% of the shares of the stock are sold short. According to 7 analysts, the average rating for PULM stock is “Buy.” momentum day trading The 12-month stock price forecast is 10.2, which is an increase of 151.23% from the latest price. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 to -2 .

PULM Overview

Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Pulmatrix’s market cap is calculated by multiplying disadvantages of a floating exchange rate PULM’s current stock price of $3.80 by PULM’s total outstanding shares of 3,639,185. Pulmatrix saw a decrease in short interest in the month of October. As of October 31st, there was short interest totaling 52,500 shares, a decrease of 19.8% from the October 15th total of 65,500 shares.

Shares of Pulmatrix Inc. more than doubled Monday, rocketing 124% on heavy volume, after the company said it entered into a “binding term sheet” with Cipla Ltd. subsidiary Cipla Technologies LLC for the development and co…

Since then, PULM stock has decreased by 53.7% and is now trading at $4.06. Pulmatrix has a short interest ratio (“days to cover”) of 0.6, which is generally considered an acceptable ratio of short interest to trading volume. According to analysts’ consensus price target of $10.00, Pulmatrix has a forecasted upside of 146.3% from its current price of $4.06. WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. Overall, this stock passed 10/33 due dilligence checks and has average fundamentals, according to our automated analysis.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style. The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style. You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security.

View All General Business

PUR1900 on track for Phase 2 study start in Q PUR3100 Phase 1 study top line data anticipated in early Q $40.7 million in cash and cash equivalents at end of Q LEXINGTON, M… This drug company with lung inhaler administered medicine appears to have bottomed and is moving some. My partner and I predict this stock is going to spike exponentially by Friday next week. Pulmatrix, Inc. doesn’t possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

The industry with the worst average Zacks Rank would place in the bottom 1%. An industry with a larger percentage of Zacks Rank #1’s and #2’s will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4’s and #5’s. The Zacks Industry Rank assigns a rating to each of the 265 X Industries based on their average Zacks Rank. Pulmatrix has received no research coverage in the past 90 days. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist.

1 Wall Street analysts have issued “buy,” “hold,” and “sell” ratings for Pulmatrix in the last twelve months. The consensus among Wall Street analysts is that investors should “buy” PULM shares. At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.51% per year. These returns cover a period from January 1, 1988 through September 12, 2022.

Pulmatrix Commences Initial-Stage Acute Migraine Study

High institutional ownership can be a signal of strong market trust in this company. In the past three months, Pulmatrix insiders have not sold or bought any company stock. MarketBeat has tracked 5 news articles for Pulmatrix this week, compared to 1 article on an average week. MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation. Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. Information is provided ‘as-is’ and solely for informational purposes and is not advice.

Intraday Data provided by FACTSET and subject to terms of use. Historical and current end-of-day data provided by FACTSET. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements. H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Pulmatrix (PULM – Research Report) today and set a price target of $5.00.

Looking for continuation and possible breakout today in PULM Pulmatrix, Inc. is a clinical stage biotechnology company, which engages in the discovery and development of novel inhaled therapeutic products for respiratory and other diseases. Pulmatrix, Inc. is a clinical-stage biotechnology company, which is focused on the discovery and development of inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs. It engages in developing Pulmazole, an inhaled anti-fungal drug for the treatment of allergic bronchop… 1 Wall Street analysts have issued 1-year price targets for Pulmatrix’s shares.

Heavy Industry & Manufacturing

Quotes displayed in real-time or delayed by at least 15 minutes. The scores are based on the trading styles of Value, Growth, and Momentum. There’s also a VGM Score (‘V’ for Value, ‘G’ for Growth and ‘M’ for Momentum), which combines the weighted average of the individual style scores into one score.

The 1-20 reverse split was announced on Tuesday, March 1st 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, March 1st 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. Other market data may be delayed by 15 minutes or more.

Plus, PULM info will be updated daily in your Zacks.com Portfolio Tracker – also free. One share of PULM stock can currently be purchased for approximately $4.06. The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 4th 2023. 44.12% of the stock of Pulmatrix is held by institutions.

Company is evaluating its iSPERSE™ orally inhaled dry powder formulation of dihydroergotamine for treatment of acute migraine and expects pharmacokinetic data from the Phase 1 study in Q LEX… Market cap is the total market value of a publicly traded company’s outstanding shares. Pulmatrix stock was originally listed at a price of $3,625.00 in Mar 21, 2014. If you had invested in Pulmatrix stock at $3,625.00, your return over the last 8 years would have been -99.9%, for an annualized return of -57.58% . Sign-up to receive the latest news and ratings for Pulmatrix and its competitors with MarketBeat’s FREE daily newsletter.

WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data. Sign Up NowGet this delivered to your inbox, and more info about our products and services. There may be delays, omissions, or inaccuracies in the Information. Zacks Earnings ESP looks to find companies that have recently seen positive earnings estimate revision activity. The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season. The industry with the best average Zacks Rank would be considered the top industry , which would place it in the top 1% of Zacks Ranked Industries.

Merus N.V. (MRUS) Reports Q1 Loss, Tops Revenue Estimates

This is a lower news sentiment than the 0.47 average news sentiment score of Medical companies. The company’s average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings. Real-time analyst ratings, insider transactions, earnings data, and more.

Pulmatrix, Inc. is a clinical stage biotechnology company engaged in the discovery and development of novel inhaled therapeutic products for respiratory and other diseases. The firm focuses on the prevention and treatment of respiratory diseases and infections. It offers products based on its proprietary dry powder delivery technology, iSPERSE, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The company was founded by David Alan Edwards, Mark J. Gabrielson, Alexander M. Klibanov, and Robert S. Langer, Jr. on June 15, 2015 and is headquartered in Lexington, MA. Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.